Publikationen in Zusammenarbeit mit Forschern von Hospital Clinico Universitario de Valencia (46)

2024

  1. Critical review of clinical data and expert-based recommendations for the use of bosutinib in the treatment of chronic myeloid leukemia

    Frontiers in Oncology, Vol. 14

  2. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  3. Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy

    Frontiers in Oncology, Vol. 14

  4. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

2023

  1. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  2. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  3. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  4. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456

  5. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients

    Viruses, Vol. 15, Núm. 10

  6. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination

    Bone Marrow Transplantation, Vol. 58, Núm. 5, pp. 567-580

  7. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors

    Expert Review of Hematology, Vol. 15, Núm. 6, pp. 477-484

  2. Breakthrough infections in MPN-COVID vaccinated patients

    Blood Cancer Journal

  3. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19

    American Journal of Hematology

  4. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2231-2239

  5. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

    Cancer, Vol. 128, Núm. 13, pp. 2441-2448

  6. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group

    American Journal of Hematology, Vol. 97, Núm. 1, pp. 30-42

  7. Second versus first wave of COVID-19 in patients with MPN

    Leukemia

  8. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients

    Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550

2021

  1. Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry

    American Journal of Hematology, Vol. 96, Núm. 10, pp. 1186-1194